Excision BioTherapeutics

company

About

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

  • 11 - 50

Details

Last Funding Type
Seed
Last Funding Money Raised
$10M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$70.75M
Excision BioTherapeutics has raised a total of $70.75M in funding over 2 rounds. Their latest funding was raised on Feb 17, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 17, 2021 Series Unknown $60M 1 Detail
Feb 2, 2021 Series A 2 Detail
Dec 20, 2019 Series Unknown $750K 1 Detail
Sep 6, 2017 Seed $10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
Excision BioTherapeutics is funded by 3 investors. Norwest Venture Partners and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Norwest Venture Partners Series Unknown
ARCH Venture Partners Series A
Gaingels Series Unknown